Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 561 - 570 of 785 studies

Metabolic and Endocrine

A Phase 3, Double-Blind, Randomized, Placebo-Controlled study of Baricitinib to delay Stage 3 Type 1 Diabetes in at-risk participants aged ≥1 to <36 years. (BARICADE-DELAY) (I4V-MC-JAJJ (BARICADE-DELAY))

Cardiovascular

Randomised EValuation of Therapies for microvAscuLar Injury in STEACS (REVITALISE)

Cardiovascular

A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM (IMB101-010 (FORTITUDE-HCM))

Evaluation and simulated pilot deployment of “TrustedMDT-Copilot”: an agentic AI copilot providing decision support to Oncology multidisciplinary team meetings

Blood

A Phase 3, Prospective, Open-label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with rVWF in Children Diagnosed with Severe Von Willebrand Disease ( rVWF Pediatric Prophylaxis Study) (TAK-577-3001)

Cancer and neoplasms

A Randomized Phase 3 Trial of IMA203 PRAME-directed TCR T-cell Therapy vs Investigator’s Choice in Unresectable or Metastatic Melanoma post ICI (IMA203-301) (SUPRAME)

DPYD polymorphisms in patients with solid tumours receiving fluoropyrimidines: A UK clinical registry

Infection Reproductive health and childbirth

A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants (C1091009)

Cancer and neoplasms

A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (CCS1477-04)

Cancer and neoplasms

A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BGB-16673-304)